AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study

RecruitingNAAges 18 Years - anyAllCentre Hospitalier Universitaire de Saint Etienne
💬

In plain words

What the trial is, and whether it could suit you

Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4. The absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available "general neuropathy" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large popula

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patient affiliated with or beneficiary of a social security system * Patient having received appropriate study information * Adult patient ≥18 years old, male or female * Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria * SN with one of the following etiologies: Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome Exclusion Criteria: * Patient unable to understand or read French * Patient refusal to participate * Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including: * Diabetes mellitus * Significant alcohol consumption * Severe chronic kidney disease (GFR \<30 ml/min) * Vitamin B12 and/or vitamin E deficiency * Vitamin B6 excess * Chemotherapy other than platinum salts * HIV infection
💊

What it tests

  • Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.
📍

Where

19 sites
Chu D Angers
Angers, France
Chu de Clermont Ferrand
Clermont-Ferrand, France
Chu de Grenoble
Grenoble, France
Chu de Lille
Lille, France
Chu de Limoges
Limoges, France
Hospices Civils de Lyon
Lyon, France
Hopitaux Universitaire de Marseille
Marseille, France
Chu de Nancy
Nancy, France

…and 11 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy